➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Baxter
Merck
Harvard Business School
Colorcon

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

MULTIHANCE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Multihance, and what generic alternatives are available?

Multihance is a drug marketed by Bracco and is included in two NDAs.

The generic ingredient in MULTIHANCE is gadobenate dimeglumine. One supplier is listed for this compound. Additional details are available on the gadobenate dimeglumine profile page.

US Patents and Regulatory Information for MULTIHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-001 Nov 23, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-004 Nov 23, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-002 Nov 23, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-003 Nov 23, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bracco MULTIHANCE MULTIPACK gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021358-002 Nov 23, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MULTIHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-001 Nov 23, 2004   Start Trial   Start Trial
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-003 Nov 23, 2004   Start Trial   Start Trial
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-004 Nov 23, 2004   Start Trial   Start Trial
Bracco MULTIHANCE gadobenate dimeglumine INJECTABLE;INTRAVENOUS 021357-002 Nov 23, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for MULTIHANCE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0230893 SPC/GB97/081 United Kingdom   Start Trial PRODUCT NAME: GADOBENATE DIMEGLUMINE; REGISTERED: UK 06099/0006 19970722
0230893 33/1998 Austria   Start Trial PRODUCT NAME: GADOBENAT DIMEGLUMIN; NAT. REGISTRATION NO/DATE: 1-22773 19981109; FIRST REGISTRATION: GB PL 06099/0006 19970722
0230893 C980024 Netherlands   Start Trial PRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722
0230893 99C0013 Belgium   Start Trial PRODUCT NAME: GADOBENAATDIMEGLUMINE; NAT. REGISTRATION NO/DATE: 3503 IE 48 F 12 19990201; FIRST REGISTRATION: GB PL 06099/0006 19970722
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
McKesson
Moodys
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.